Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya

Mycoses

Volumn 54, Issue 5, 2011, Pages

  Mdodo, Rennatus ^a   Moser, Stephen A ^b   Jaoko, Walter ^c   Baddley, John ^d   Pappas, Peter ^d   Kempf, Mirjam Colette ^a   Aban, Inmaculada ^a   Odera, Susan ^c   Jolly, Pauline ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF NAIROBI   (Kenya)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Amphotericin B; Cryptococcus neoformans; Fluconazole; Kenya; Serotypes; Susceptibility

Indexed keywords

AMPHOTERICIN B; BROMOTHYMOL BLUE; FLUCONAZOLE; FLUCYTOSINE; RAVUCONAZOLE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CEREBROSPINAL FLUID CULTURE; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; FEMALE; FUNGUS GROWTH; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; KENYA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SEROTYPE;

ADULT; ANTIFUNGAL AGENTS; CEREBROSPINAL FLUID; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIA; FEMALE; HIV INFECTIONS; HUMANS; KENYA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

FILOBASIDIELLA NEOFORMANS;

EID: 80052821910     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01946.x     Document Type: Article

References (19)

1. Mitchell TG, Perfect JR. Cryptococcosis in the AIDS era-100years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8: 515-48.
2. McCarthy K, Morgan J, Wannemuehler K et al. Population-based surveillance for cryptococcosis in an antiretroviral-naïve South African province with high HIV seroprevalence. AIDS 2006; 20: 2199-206.
3. Bii C, Makimura K, Abe S et al. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya. Mycoses 2007; 50: 25-30.
4. Franzot SP, Salkin IF, Casadevall A. Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol 1999; 37: 838-40.
5. Casadevall A, Perfect JR (ed.), Epidemiology, in Cryptococcus neoformans. Washington, DC: American Society for Microbiology, 1998: 351-80.
6. Brandt M E, Pfaller MA, Hajjeh RA et al. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 2001; 45: 3065-9.
7. Park BJ, Wannemuehler KA, Marston B J, Govender N, Pappas P G, Chiller T M. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23: 525-30.
8. Bicanic T, Harrison T S. Cryptococcal meningitis. Br Med Bull 2005; 72: 99-118.
9. Okongo M, Morgan D, Mayanja B, Ross A, Whitworth J. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int J Epidemiol 1998; 27: 698-702.
10. French N, Gray K, Watera C et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16: 1031-8.
11. Pfaller MA, Messer SA, Boyken L et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43: 2163-7.
12. Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother 2004; 54: 563-5.
13. Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006; 43: 1069-73.
14. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard, 3rd edn, Document M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2007.
15. Nguyen MH, Yu CY. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother 1998; 42: 471-2.
16. Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol 1982; 15: 535-7.
17. Kwon-Chung KJ, Bennett JE. High prevalence of Cryptococcus neoformans var. gattii in tropical and subtropical regions. Zentralbl Bakteriol Mikrobiol Hyg [A] 1984; 257: 213-8.
18. Direct Relief International: Diflucan Partnership Program [WWW document], 2001. URL [accessed on 25 January 2010].
19. Makimura K, Oguri T, Mikami Y et al. Multicenter evaluation of commercial frozen plates for microdilution both antifungal susceptibility testing of yeasts and comparison of MIC limits recommended in NCCLS M27-A2. Microbiol Immunol 2005; 49: 97-106.